Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc.

3.26
EUR
0.00
(0.00%)
-0.52EPS
703.45MMarket Cap
Feb 25Next Earn
Aclaris Therapeutics, Inc.
GETTEX:8AT
(Gettex)

Recent

price

3.26

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
- -
- -
- -
- -
0.06
0.19
0.1
0.15
0.12
0.46
0.45
0.24
0.06
0.05
Revenue per Share
-0.65
-0.99
-3.79
-2.25
-2.44
-4.03
-3.9
-1.2
-1.6
-1.33
-1.27
-1.71
-0.53
-0.59
Basic EPS, GAAP
-0.46
-0.76
-3.42
-1.63
-1.99
-3.1
-2.37
-0.92
-0.92
-1.05
-1.14
-0.72
-0.39
-0.55
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.47
-1.07
4.59
6.5
7.3
5.22
1.69
0.83
3.22
2.96
2.22
1.44
0.86
1.11
Book Value per Share
-0.47
-1.07
4.59
6.5
6.46
4.59
1.51
0.68
3.11
2.86
2.21
1.44
0.86
1.11
Tangible Book Value per Share
11
11
6
21
28
33
41
43
57
65
70
77
123
136
Basic Weighted Avg Shares
- -
- -
- -
- -
2
6
4
6
7
30
31
19
8
6
Sales/Revenue/Turnover
- -
- -
- -
- -
-3,170.59
-1,378.31
-2,172.23
-748.52
-967.08
-286.21
-372.22
-280.59
-946.52
-1,412.4
Operating Margin (%)
- -
- -
- -
- -
- -
2
6
1
1
1
1
1
- -
- -
Depreciation Expense
-5
-9
-21
-48
-69
-133
-161
-51
-91
-87
-88
-132
-65
-80
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
-4,071.48
-2,157.99
-3,817.22
-787.03
-1,343.96
-292.11
-283.15
-705.48
-829.58
-1,244.09
Profit Margin (%)
13
15
85
132
187
152
61
43
182
210
98
94
68
99
Working Capital
- -
- -
- -
- -
- -
30
- -
11
- -
- -
- -
- -
- -
- -
LT Debt
-9
-21
93
169
225
215
70
38
197
198
157
156
103
167
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-36.7
-34.72
-60.28
-113.22
-94.86
-77.33
-44.01
-49.88
-84.46
-50.2
-55.51
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
140
140
151
Market Capitalization
519
788
797

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
110
98
123
Cash, Cash Equivalents & STI
105
92
114
Accounts Receivable, Net
- -
- -
9
Inventories
- -
- -
- -
Total Current Liabilities
27
28
24
Payables & Accruals
19
19
13
ST Debt
- -
- -
- -
Deferred Revenue
4
4
4

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
36.7%
73.81%
-33.73%
Free Cash Flow
18.16%
7.13%
-15.68%
Net Income, GAAP
29.72%
14.8%
-50.84%
Sales/Revenue/Turnover
- -
50.22%
-58.19%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2
3
4
9
19
2025
1
2
3
1
8
2026
2
2
1
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.24
-0.15
-0.11
-1.01
-1.71
2025
-0.12
-0.13
-0.12
-0.16
-0.53
2026
-0.15
-0.15
-0.12
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Aclaris Therapeutics, Inc. (Nasdaq: ACRS) is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated inflammatory diseases and cancers. The company offers a pipeline of novel drug candidates, including ATX-104, a topical JAK1 inhibitor in Phase 2 trials for alopecia areata; zunsemetinib (formerly ATI-2138), an oral MK2 inhibitor in Phase 2 for atopic dermatitis, hidradenitis suppurativa, and rheumatoid arthritis; and ATX-032, an inhaled JAK1 inhibitor for moderate-to-severe asthma; as well as earlier-stage assets like ATX-1403 (S1P1/3 modulator) and ATX-2441 (BTLA agonist antibody). These therapies target dermatological, respiratory, and oncology indications through proprietary platforms emphasizing precision immunology and targeted modulation. Founded in 2012 and headquartered in Malvern, Pennsylvania, Aclaris operates primarily in the United States with a focus on advancing its immunology and oncology portfolios for patients underserved by existing therapies.[web:previous] In the past two years, Aclaris has undergone significant strategic shifts, including the spin-off of its contract research organization business into a separate entity, FocusCRO, in October 2023 to streamline operations and concentrate resources on its drug pipeline; a corporate reorganization in 2024 that reduced headcount and costs amid pipeline prioritization; and the appointment of new leadership, such as CEO Neal Fowler in early 2024, to drive clinical execution.[web:previous] The company secured $90 million in financing through a registered direct offering in June 2024 to fund ongoing Phase 2 trials, and recently advanced zunsemetinib into a Phase 2b trial for hidradenitis suppurativa in late 2025 while discontinuing less viable assets to focus on high-potential programs. These changes position Aclaris to accelerate development in immunology segments, targeting dermatology clinics, rheumatologists, and pulmonologists globally through partnerships and potential commercialization. No major acquisitions or name changes have occurred recently.[web:previous]

Company News

  • Why is Aclaris Therapeutics Stock Trading Lower on Monday?

  • Aclaris Therapeutics, Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

  • Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)

  • Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)

  • Aclaris Therapeutics to Participate in the Jefferies Global Healthcare Conference

  • Aclaris Therapeutics (NASDAQ:ACRS) vs. Oncocyte (NASDAQ:IMDX) Financial Contrast

  • Aclaris Therapeutics (ACRS) Reports Q3 Loss, Beats Revenue Estimates

  • Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update

  • Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b

  • Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma Transcript

  • Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants

  • Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma

  • Aclaris Therapeutics, Inc. (ACRS) – What Are Analysts Saying About This Stock?

  • Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

  • Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?

  • Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

  • Deutsche Bank AG Makes New Investment in Aclaris Therapeutics, Inc. $ACRS

  • Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade

  • Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

  • Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates